Last reviewed · How we verify
Tenofovir + lamivudine + raltegravir
Tenofovir and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs) that block HIV replication by inhibiting viral DNA synthesis. Raltegravir is an integrase strand transfer inhibitor (INSTI) that blocks HIV replication by inhibiting viral integration into the host genome.
Tenofovir and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs) that block HIV replication by inhibiting viral DNA synthesis. Raltegravir is an integrase strand transfer inhibitor (INSTI) that blocks HIV replication by inhibiting viral integration into the host genome. Used for Treatment of HIV-1 infection in adults and children, Prevention of mother-to-child transmission of HIV.
At a glance
| Generic name | Tenofovir + lamivudine + raltegravir |
|---|---|
| Sponsor | ANRS, Emerging Infectious Diseases |
| Drug class | NRTI + INSTI |
| Target | HIV integrase |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
Tenofovir and lamivudine work by competing with the natural building blocks of DNA, thereby preventing the virus from replicating. Raltegravir works by blocking the enzyme integrase, which is essential for the virus to integrate its genetic material into the host cell's DNA.
Approved indications
- Treatment of HIV-1 infection in adults and children
- Prevention of mother-to-child transmission of HIV
Common side effects
- Nausea
- Diarrhea
- Headache
- Fatigue
- Abdominal pain
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 (PHASE3)
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
- Research on the Psychological Status of Patients With HIV-1 Infection
- Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses (PHASE2)
- A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed (PHASE2)
- B-free Multistage Trial (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: